<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oral antimicrobial options for acute simple cystitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oral antimicrobial options for acute simple cystitis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Oral antimicrobial options for acute simple cystitis</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Dose</td> <td class="subtitle1_left">Duration</td> <td class="subtitle1_left">Comment</td> </tr> <tr> <td class="subtitle2_left" colspan="4">First-line options</td> </tr> <tr> <td class="indent1">Nitrofurantoin monohydrate/macrocrystals (Macrobid)<sup>*</sup></td> <td>100 mg orally twice daily</td> <td> <p>Females: 5 days<sup>¶</sup></p> Males: 7 days</td> <td> <ul> <li>Retains activity against some MDR organisms</li> <li>Avoid if: <ul> <li>Concern for early pyelonephritis</li> <li>CrCl &lt;30 mL/minute</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole<sup>Δ</sup></td> <td>One double-strength tablet (160 mg/800 mg) orally twice daily</td> <td> <p>Females: 3 days<sup>¶</sup></p> Males: 7 days</td> <td> <ul> <li>Useful for males with concern for possible prostatitis</li> <li>Avoid if: <ul> <li>Regional prevalence of resistance known to be &gt;20%</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Fosfomycin</td> <td>3 g of powder mixed in water and administered orally</td> <td>Single dose<sup>¶</sup></td> <td> <ul> <li>Retains activity against some MDR organisms</li> <li>Avoid if: <ul> <li>Concern for early pyelonephritis</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Pivmecillinam</td> <td>400 mg orally three times daily</td> <td> <p>Females: 3 to 5 days<sup>¶</sup></p> Males: 7 days</td> <td> <ul> <li>Retains activity against some MDR organisms</li> <li>Avoid if: <ul> <li>Concern for early pyelonephritis</li> </ul> </li> <li>Not available in the United States</li> <li>Not well studied in males</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Alternatives: Other beta-lactams</td> </tr> <tr> <td class="indent1">Amoxicillin-clavulanate</td> <td>500 mg orally twice daily</td> <td> <p>Females: 5 to 7 days<sup>¶</sup></p> Males: 7 days</td> <td> <ul> <li>Dose is based on amoxicillin component</li> </ul> </td> </tr> <tr> <td class="indent1">Cefadroxil</td> <td>500 mg orally twice daily</td> <td> <p>Females: 5 to 7 days<sup>¶</sup></p> Males: 7 days</td> <td> </td> </tr> <tr> <td class="indent1">Cefpodoxime</td> <td>100 mg orally twice daily</td> <td> <p>Females: 5 to 7 days<sup>¶</sup></p> Males: 7 days</td> <td> </td> </tr> <tr> <td class="indent1">Cephalexin </td> <td>500 mg orally twice daily<sup>◊</sup></td> <td> <p>Females: 5 to 7 days<sup>¶</sup></p> Males: 7 days</td> <td> </td> </tr> <tr> <td class="indent1">Cefdinir</td> <td>300 mg orally twice daily</td> <td> <p>Females: 5 to 7 days<sup>¶</sup></p> Males: 7 days</td> <td> <ul> <li>Does not achieve high urinary concentrations but may be sufficient to treat cystitis with susceptible organisms</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Alternatives: Fluoroquinolones</td> </tr> <tr> <td class="indent1">Ciprofloxacin</td> <td> <p>250 mg orally twice daily</p> <p>or</p> 500 mg extended release orally once daily</td> <td> <p>Females: 3 days<sup>¶</sup></p> Males: 5 days</td> <td> <ul> <li>Useful for males with concern for possible prostatitis<sup>§</sup></li> <li>Extended-release formulation not available in the United States</li> </ul> </td> </tr> <tr> <td class="indent1">Levofloxacin</td> <td>250 mg orally once daily</td> <td> <p>Females: 3 days<sup>¶</sup></p> Males: 5 days</td> <td> <ul> <li>Useful for males with concern for possible prostatitis<sup>§</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>These options for oral antimicrobial therapy of acute simple cystitis apply to adults and adolescents of all ages. Doses listed are for individuals with normal kidney function; dose adjustments may be needed for individuals with kidney impairment.</p>
First-line options strike a favorable balance between efficacy and adverse effects (including the risk of selecting for resistant organisms). The choice among them should be individualized to patient circumstances (allergy, tolerability, expected adherence), local community resistance prevalence, availability, cost, and patient and provider threshold for failure. If the patient has taken one of the agents in the preceding three months, a different one should be selected. Beta-lactams are second-line agents because they are less effective and have more potential adverse effects. Although fluoroquinolones are very effective, associated adverse effects and increasing resistance rates mitigate their utility; we only use them if other agents cannot be used or in males with concern for possible prostatitis.</div><div class="graphic_footnotes"><p>CrCl: creatinine clearance; MDR: multidrug resistant.</p>
<p>* Nitrofurantoin is also available as nitrofurantoin macrocrystals (Macrodantin), which is dosed differently. Refer to the Lexicomp drug information monograph for nitrofurantoin included within UpToDate.</p>
<p>¶ For females with urinary tract abnormalities, immunocompromising conditions, or poorly controlled diabetes mellitus, it is reasonable to use a longer duration of therapy (eg, 7 days). If a longer duration of fosfomycin is needed (ie, more than a single dose), additional doses are administered every 2 to 3 days for up to 3 doses.</p>
<p>Δ Trimethoprim 100 mg orally twice daily for 3 days is a potential option for individuals who have a sulfonamide (but not trimethoprim) allergy if regional prevalence of resistance is known to be &lt;20%.</p>
<p>◊ Cephalexin can also be dosed at 250 mg orally every 6 hours.</p>
§ For males who have more severe cystitis symptoms or concern about early involvement of the prostate (eg, recurrent UTI with the same pathogen, equivocal prostatic tenderness), we use higher doses of fluoroquinolones (ciprofloxacin 500 mg orally twice daily or 1000 mg extended release once daily, or levofloxacin 750 mg orally once daily).</div><div id="graphicVersion">Graphic 143609 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
